Lupin Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 10, 2026

Key Highlights

The Latest Trading Price of Lupin Ltd is ₹ 2248 as of 10 Jun 15:30 . The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lupin Ltd changed from ₹ 46318 crore on March 2021 to ₹ 92522 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Lupin Ltd for the Mar '26 is ₹ 7615 crore as compare to the Dec '25 revenue of ₹ 7282 crore. This represent the growth of 4.57% The revenue of Parmax Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Lupin Ltd for the Mar '26 is ₹ 2494 crore as compare to the Dec '25 ebitda of ₹ 1949 crore. This represent the growth of 27.95% The ebitda of Parmax Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Lupin Ltd changed from ₹ 805.54 crore to ₹ 1468 crore over 8 quarters. This represents a CAGR of 35.03% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Lupin Ltd changed from 23.43 % on March 2021 to 13.79 % on March 2025 . This represents a CAGR of -10.06% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Lupin Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Lupin Ltd or Parmax Pharma Ltd?

Market cap of Lupin Ltd is 102,817 Cr while Market cap of Parmax Pharma Ltd is 20 Cr

What are the key factors driving the stock performance of Lupin Ltd and Parmax Pharma Ltd?

The stock performance of Lupin Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Parmax Pharma Ltd?

As of June 10, 2026, the Lupin Ltd stock price is INR ₹2248.7. On the other hand, Parmax Pharma Ltd stock price is INR ₹53.81.

How do dividend payouts of Lupin Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Lupin Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.